Skip to main content
. 2020 Jul 21;5(10):1700–1705. doi: 10.1016/j.ekir.2020.07.011

Figure 2.

Figure 2

Overall incidence of all acute kidney injury (AKI), sustained AKI, and programmed death ligand-1 (PD-L1)–related AKI in patients receiving atezolizumab, durvalumab, and avelumab. Among the 347 patients who received atezolizumab, 64 patients (18%) experienced any AKI, 25 (7%) had sustained AKI, and 4 (1%) had PD-L1–related AKI. Among the 153 patients who received durvalumab, 21 (14%) experienced any AKI, 5 (3%) had sustained AKI, and 1 (1%) experienced PD-L1–related AKI. Among the 99 patients who received avelumab, 19 (19%) experienced any AKI, 6 (6%) had sustained AKI, and none had PD-L1–related AKI.